Spironolactone topique 1 % (gel) face à Gel associant minoxidil 5 % et spironolactone 1 %
1 essai les comparent directement, sur les mêmes patients. Voir Spironolactone topique 1 % (gel) · Voir Gel associant minoxidil 5 % et spironolactone 1 %
Un seul essai de fiabilité limitée (Abdel-Raouf 2021), chez 60 adultes de 18 à 45 ans atteints d'alopécie androgénétique (39 hommes, 21 femmes), a comparé un gel de spironolactone 1 % seul à un gel associant minoxidil 5 % et spironolactone 1 %. À un an, tous les patients sous gel associé voient leurs cheveux repousser (100 %, 20 sur 20), contre 80 % (16 sur 20) sous spironolactone seule, un écart significatif. Ce résultat reste à confirmer.
Abdel-Raouf 2021
Essai randomisé, risque de biais élevé. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.
| Critère | Spironolactone topique 1 % (gel) | Gel associant minoxidil 5 % et spironolactone 1 % | Écart |
|---|---|---|---|
| Taux de repousse clinique | 80 % (16 sur 20)Voir la citationof AGA. The average time of hair loss in patients, were 26.36 ± 21.9 months. In group I treated with topical minoxidil gel 5%, clinical response were in 90% of the patients, four of them have excellent response, six have good response , two have fair response and six have poor response. In group II treated with topical spironolactone gel 1%, clinical improvement were in 80% of the patients, five of them have excellent response, four have good response, and seven patients have poor response. In group III treated with combined topical spironolactone 1% and minoxidil 5% gel, clinical improvement were in 100% of the patients, eight of them have excellent response, ten have good response, and two patients have fair response.. In comparison between group I and group II, there was insignificant difference between them (p= 0.516) while there was a significant difference between group I and group III, group II and group III (p= 0.035, p= 0.003 respectively) (Figs. 1). Abdel-Raouf H, Aly UF, Medhat W et al.. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.. Dermatol Ther 2021, DOI 10.1111/dth.14678. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | 100 % (20 sur 20)Voir la citationof AGA. The average time of hair loss in patients, were 26.36 ± 21.9 months. In group I treated with topical minoxidil gel 5%, clinical response were in 90% of the patients, four of them have excellent response, six have good response , two have fair response and six have poor response. In group II treated with topical spironolactone gel 1%, clinical improvement were in 80% of the patients, five of them have excellent response, four have good response, and seven patients have poor response. In group III treated with combined topical spironolactone 1% and minoxidil 5% gel, clinical improvement were in 100% of the patients, eight of them have excellent response, ten have good response, and two patients have fair response.. In comparison between group I and group II, there was insignificant difference between them (p= 0.516) while there was a significant difference between group I and group III, group II and group III (p= 0.035, p= 0.003 respectively) (Figs. 1). Abdel-Raouf H, Aly UF, Medhat W et al.. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: Clinical, histopathological, and physicochemical study.. Dermatol Ther 2021, DOI 10.1111/dth.14678. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Probablement réel |